Tempest's TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage ...

Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target ...

Caitlin Fowler took on a lofty charity challenge to go the distance for partner Lucy Stewart who has a rare lifechanging auto ...

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by ...

Myasthenia gravis affects about 30 out of every 100,000 people in Canada, according to the Myasthenia Gravis Society of ...

On July 6, 2026, TG Therapeutics, Inc. (NASDAQ:TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi ...

UCB, a global biopharmaceutical company, today announced the recipients of its annual UCB Myasthenia Gravis Scholarship,™ awarding 15 scholarships to individuals in the United States who are living ...

Instead, the seemingly botched experiment helped launch a new generation of therapies for autoimmune diseases afflicting ...

UCB S.A. UCBJY UCBJF on Wednesday presented new data at the International Congress on Neuromuscular Diseases 2026 showing that long-term treatment with rozanolixizumab and zilucoplan delivered ...

TG Therapeutics TGTX announced that it has initiated a phase II study evaluating Briumvi (ublituximab-xiiy) for the treatment of adult patients with treatment-resistant schizophrenia. Shares of the ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...